SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma
NCT07668570
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
36
Enrollment
OTHER
Sponsor class
Conditions
HCC - Hepatocellular Carcinoma
Interventions
RADIATION:
Stereotactic Body Radiation Therapy (SBRT)
DRUG:
QL1706
Sponsor
Hebei Medical University Fourth Hospital